Oramed Pharmaceuticals Inc. (ORMP)
ORMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/0001213900-26-034835-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ORMP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001176309 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | $64.0M |
| Operating income | -$15.1M |
| Net margin | 3202.5% |
| Operating margin | -754.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $45.9M |
| Total assets | $230.9M |
| P/E (computed) | 2.6× |
| P/S (computed) | 84.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $28.9M cash; operating cash flow -$789K a quarter. | Report 2026-09-30 |
| Shares outstanding | 43,485,942 (2026-11-11); 39,802,455 a year earlier; 40,338,979 three years earlier. | Cover page 2026-11-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-04-12 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $942K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | $18.4M | $426K | $28.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-06-30 | Not filed | $78.2M | -$200K | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q2 2026 2026-03-31 | Not filed | $38.3M | -$2.9M | $13.2M | No debt tags | Needs four quarters | 10-Q 2026-05-19 |
| Q1 2026 2025-12-31 | $0 | $10.0M | -$466K | $45.9M | $652K | $2.0M | 10-K 2026-03-26 |
| Q1 2026 2025-09-30 | $0 | $48.4M | -$1.6M | $52.2M | $1K | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2025 2025-06-30 | $0 | $13.3M | -$3.5M | $15.8M | $34K | Needs four quarters | 10-Q 2026-08-10 |
| Q2 2025 2025-03-31 | $2.0M | -$7.6M | -$3.5M | $74.5M | $36K | Needs four quarters | 10-Q 2026-05-19 |
| Q1 2025 2024-12-31 | Not filed | -$10.2M | -$1.9M | $54.4M | $329K | Needs four quarters | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2024-03-18 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-26 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-17 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 951 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.9% |
| 1 month | -11.0% |
| 3 months | -15.3% |
| Year to date | +30.2% |
| 1 year | +54.6% |
| From 52-week high | -30.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| SLGL | Sol-Gel Technologies Ltd. | $54.96 | -0.29% | $179.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier